Data as of Dec 06
| -0.06 / -0.91%|
The 1 analysts offering 12-month price forecasts for Nymox Pharmaceutical Corp have a median target of 9.50, with a high estimate of 9.50 and a low estimate of 9.50. The median estimate represents a +45.71% increase from the last price of 6.52.
The current consensus among 1 polled investment analysts is to Buy stock in Nymox Pharmaceutical Corp. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.